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SUMMARY
Obesity develops due to altered energy homeostasis favoring fat storage. Here we describe a novel
transcription co-regulator for adiposity and energy metabolism, TRIP-Br2 (also called
SERTAD2). TRIP-Br2 null mice are resistant to obesity and obesity-related insulin resistance.
Adipocytes of the knockout (KO) mice exhibited greater stimulated lipolysis secondary to
enhanced expression of hormone sensitive lipase (HSL) and β3-adrenergic (Adrb3) receptors. The
KOs also exhibit higher energy expenditure due to increased adipocyte thermogenesis and
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oxidative metabolism by up-regulating key enzymes in respective processes. Our data show for
the first time that a cell cycle transcriptional co-regulator, TRIP-Br2, modulates fat storage
through simultaneous regulation of lipolysis, thermogenesis and oxidative metabolism. These data
together with the observation that TRIP-BR2 expression is selectively elevated in visceral fat in
obese humans suggests that this transcriptional co-regulator is a novel therapeutic target for
counteracting the development of obesity, insulin resistance and hyperlipidemia.
INTRODUCTION
Obesity and its related complications are associated with high morbidity and mortality
making it a pathologic condition of global significance1,2. Understanding the regulation of
the factors that control storage, mobilization, and utilization of excess energy in adipocytes
may lead to the development of potential therapies for obesity and related diseases.
In mammals, white adipose tissue (WAT) is the primary energy reservoir and a major source
of metabolic fuel and regulatory adipokines3–5. On the other hand, brown adipose tissue
(BAT) is specialized in energy expenditure and thermogenesis through high levels of fatty
acid oxidation in numerous mitochondria, and the expression of uncoupling protein 1
(UCP-1)6.
Transcriptional control of cellular energy metabolic pathways in mammals is achieved by
the coordinated action of numerous transcription factors and associated co-regulators7,
which integrate signals from dietary, metabolic and endocrine pathways to control target
gene expression8. The co-regulators, which can have either positive (co-activators such as
PGC1α and β) or negative (co-repressors such as SRC-2 and RIP140) gene transcriptional
effects on downstream targets9,10, play a crucial role in controlling fat accretion8 primarily
through the modulation of PPARγ activity, the master regulator of adipocyte differentiation
and lipid storage11.
We identified a novel co-regulator of the E2F1/DP1/RB gene transcription complex
involved in cell cycle progression. TRIP-Br2 (also known as SERTAD2-SERTA domain
containing 2)12, is a member of a novel family of mammalian transcriptional co-regulators
comprised of five members13, four of which have been shown to modulate E2F-dependent
transcriptional activities12,14,15. While the role of TRIP-Br2 in adipose tissue is virtually
unknown, it has been proposed to recruit PHD zinc finger- and/or bromodomain-containing
transcriptional co-regulators12,16, such as p300/CBP17 and KRIP-118, to E2F1/DP1
transcription complexes assembled on E2F-responsive promoters. Recent evidence suggests
that besides its role in cell cycle regulation, the E2F1/DP1 transcriptional complex regulates
adipocyte biology and energy metabolism19,20.
We report that the expression of TRIP-Br2 in adipose tissues is necessary for the
development of diet- and age-induced obesity while its ablation enhances adipocyte
lipolysis, thermogenesis and oxidative metabolism without ectopic TG storage or increase in
serum nonesterified fatty acid levels. To our knowledge, this is the first report of a cell cycle
transcriptional co-regulator that modulates fat storage by simultaneously regulating multiple
processes including lipolysis, thermogenesis and oxidative metabolism leading to enhanced
fatty acid turnover in adipocytes, in contrast to the other known described co-regulators
including PGC1α, 1β, SRC-2 and RIP140 which act by regulating adipocyte lipogenesis and
differentiation. The elevated expression of TRIP-Br2 in visceral fat in obese humans and its
significant correlation with indices of glucose homeostasis suggests that this transcriptional
co-regulator is a novel target to treat obesity and its related complications.
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RESULTS
Elevated TRIP-Br2 in fat tissue in obesity
Consistent with a potential role in adiposity, gene and protein expression of TRIP-Br2 was
significantly and selectively up-regulated in BAT, epididymal (visceral) and subcutaneous
WAT in high fat diet (HFD) fed male C57BL/6J mice compared to low fat diet (LFD) fed
controls (Fig. 1a; Supplementary Fig. 1a). Similarly, TRIP-Br2 expression was selectively
up-regulated in epididymal and subcutaneous adipose tissues from 12 week old obese ob/ob
mice (Fig. 1b, Supplementary Fig. 1b), and down-regulated in mice on a calorie restricted
(CR) diet (Fig 1c). Interestingly, a significantly higher expression of TRIP-Br2 was evident
in the visceral (omental) fat from obese individuals, especially those with predominant
visceral fat accumulation (Fig 1d, Supplementary Fig. 2a). TRIP-Br2 expression in visceral
fat was significantly correlated with visceral but not subcutaneous fat area (Fig. 1e, Table 1)
in both genders (Supplementary Fig. 2b, Supplementary Table 1, Supplementary Table 2)
and independently of the presence of impaired glucose tolerance or diabetes, or the
treatment modalities of these conditions. The correlation of TRIP-Br2 expression in visceral
fat, even after adjustment for visceral fat area, remained significant for fasting plasma
insulin, glucose utilization during euglycemic-hyperinsulinemic clamp, and HbA1c,
suggesting independent dual roles of TRIP-Br2 in the modulation of adiposity and glucose
homeostasis (Table 1, Supplementary Table 2). In both genders, the obesity-adjusted odds of
diabetes progressively increased from the first to the fourth quartile of TRIP-Br2 visceral fat
expression, with OR of 4.6 (95% CI 1.1–18.6) for Q2, 5.1 (1.2–21.4) for Q3, and 9.5 (2.2–
41.1) for Q4 (Fig. 1f).
TRIP-Br2 KO mice are resistant to development of obesity
To elucidate the physiological role of TRIP-Br2, we initiated studies in mice due to the
limitations in performing mechanistic studies in human tissues. We investigated gene-trap
targeted TRIP-Br2 knockout (KO) males on the original 129SvJ founder background21 and
on the C57BL/6J background and used the latter for our studies. Successful ablation was
confirmed by the virtual absence of TRIP-Br2 gene and protein expression, while the
expression of TRIP-Br 1/3/4 remained unaltered (Supplementary Fig. 3). To potentially
unmask the phenotype, we placed the mice on either a LFD (10% fat by kcal) or HFD (60%
fat by kcal) for 12 weeks. The KO mice on the LFD exhibited a trend to reduce (~10%,
p=0.05) their body weights (Fig. 1g, left). However, on the HFD, the KO mice were
significantly leaner (Fig. 1g, right). At the end of the HFD, the KO mice showed little
change in their body weights and were similar to that of the WTs on the LFD (p=0.92) (Fig.
1g). We also observed a protection against weight gain in the KOs even when maintained on
the 129Sv background, which is known to resist diet-induced obesity22 (Fig. 1h).
Interestingly, knocking out TRIP-Br2 also protected the mice from age-induced obesity
(WT: 51.2 ± 2.7; Het: 47.6 ± 3.9; KO: 43.9 ± 1.9; WT vs KO, p<0.01). Food intake
(Supplementary Fig. 4a), gene expression of appetite regulating peptides in the
hypothalamus (Supplementary Fig. 4b) and the ability of the intestine to absorb fat23 were
similar between groups (Supplementary Fig. 5).
The lower body weight of TRIP-Br2 KO mice was largely accounted for by a reduction in
WAT weight (Fig. 1i, Supplementary Fig. 6) without an alteration in lean body mass and
body length in HFD fed mice (Fig. 1i, 1j). On the LFD, the lack of a significant decrease in
body weight in the KOs (Fig. 1g) was likely masked by an increase in their lean body mass
despite a significant reduction in the percent of fat mass (Supplementary Fig. 7) indicating
protection from diet-and age-induced obesity primarily due to lower fat mass.
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TRIP-Br2 KO mice are resistant to detrimental effects of obesity
TRIP-Br2 KO mice fed a HFD exhibited improved glucose tolerance (Fig. 2a, left), and
insulin sensitivity (Fig. 2a, right), and lower fasting glucose and insulin levels (Fig. 2b).
Further, the fed serum adiponectin levels, 24, were significantly higher in KO mice on the
HFD (Fig. 2b). Consistently, adiponectin mRNA levels were higher in the HFD KO mice
compared to WT (Fig. 2b). Increased adipocyte volume and number are positively correlated
with leptin production25. The HFD-induced 4.5-fold increase in serum leptin levels in WT
mice (Fig. 2b) was also reflected by higher adipose leptin mRNA levels, while serum leptin
levels remained low in the HFD-fed KOs. TRIP-Br2 KO mice exhibited significantly lower
fed and fasting serum cholesterol and a trend to decrease triglyceride (TG) levels on HFD
(Fig. 2b, Supplementary Fig 9b). Despite the increased lipolysis in TRIP-Br2 KO mice
(discussed below), serum non-esterified fatty acid (NEFA) levels remained in the normal
range in KO mice on HFD diet (Supplementary Fig. 9b).
In contrast, the TRIP-Br2 KO mice fed a LFD showed a trend toward improved insulin
sensitivity and a mild metabolic phenotype probably due to an insignificant reduction in
their body weights (Fig. 1g, Supplementary Fig. 8, Supplementary Fig. 9a, 9b). To confirm
the effect of TRIP-Br2 KO on insulin sensitivity, we stimulated LFD-fed mice in vivo or
differentiated adipocytes over-expressing TRIP-Br2 in vitro with insulin and observed that
expression of proteins in the insulin signaling pathway were not significantly different
between the two groups in the liver and muscle (Supplementary Fig 10) as well as in
differentiated adipocytes (Supplementary Fig. 11).
Chronic exposure of mice to HFD causes fatty liver (steatosis)26. Feeding a HFD increased
liver mass only in the WTs (Fig. 1g) while in the KOs, the livers exhibited smaller lipid-
containing vacuoles (Fig. 2c, left) and reduced TG content (Fig. 2c, right).
Obesity is associated with an increase in macrophage infiltration in visceral adipose
tissue27,28. Adipose tissues from TRIP-Br2 KO mice on the HFD exhibited 57% less
adipose tissue macrophage (ATM) infiltration (Fig. 2d, left and middle). Consistently, the
mRNA expression of macrophage marker, F4/80 and monocyte chemoattractant protein-1
(MCP-1) was significantly lower in WAT of TRIP-Br2 KO mice (Fig. 2d, right). These data
suggest TRIP-Br2 is one factor that mediates the detrimental effects of HFD-induced obesity
such as glucose intolerance, insulin resistance, changes in adiponectin, leptin and serum
lipid levels, hepatic steatosis and adipose tissue inflammation.
Reduced adipocyte size in TRIP-Br2 KO mice
A decrease in adipose tissue mass could result either from a reduction in adipocyte size and/
or a reduction in adipocyte number due to impaired differentiation29. The mRNA levels of
adipogenic transcription factors30 as well as late markers of adipocyte differentiation were
not significantly different in WAT between groups suggesting normal adipocyte
differentiation in both fat depots (Supplementary Fig. 12a). In addition, no significant
differences were observed in morphology or lipid accumulation, nor in mRNA expression of
early and late adipogenesis markers in TRIP-Br2 over-expressing or TRIP-Br2 KD 3T3-L1
cells differentiated in vitro (Supplementary Fig. 12b, 12c). These results suggest that TRIP-
Br2 is not important for adipocyte differentiation. A down-regulation of endogenous TRIP-
Br2 expression during the differentiation of WT adipocyte (Supplementary Fig. 13) argues
for a putative repressor role in mature adipocytes.
Instead, histological analyses revealed a significantly greater frequency of small adipocytes
and a lower frequency of midsized and large adipocytes in epididymal WAT from the KO
mice on HFD (Fig. 2e, 2f, Supplementary Fig. 14). Thus, TRIP-Br2 ablation leads to
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adipocyte hypotrophy due to lower TG accumulation (Fig. 2f, left) and smaller adipocyte
size rather than impaired adipocyte differentiation.
Absence of TRIP-Br2 increases fat lipolysis
We next examined whether the marked decrease in adipocyte cell size in the KO mice is due
to alterations in lipolysis or lipogenesis. While no differences were detected either in the rate
of lipogenesis or gene expression of lipogenesis markers31 in epididymal adipocytes
between groups (Supplementary Fig. 15), β-adrenergic agonist (isoproterenol)-stimulated
lipolysis was significantly higher in adipocytes from TRIP-Br2 KO mice fed a LFD or HFD
(Fig. 3a, Supplementary Fig. 16). Further, while HFD feeding blunted the isoproterenol-
stimulated lipolytic response of WT adipocytes, the adipocytes from TRIP-Br2 KOs fed
either diet remained sensitive (Supplementary Fig. 16). This observation was confirmed by
lipolysis assay in in vitro differentiated TRIP-Br2 KD or over-expressing 3T3-L1 cells (Fig.
3b). To further confirm the lipolysis changes observed in vitro or ex vivo, we measured the
lipolysis rate in vivo either by IP injection of the CL316342 compound32, a β3-adrenergic
agonist, or by the heavy water labeling technique33,34.The two approaches independently
confirmed a significant increase in in vivo lipolysis rate in the TRIP-Br2 KO mice (Fig. 3c,
3d). Analyses of key lipolytic genes, in epididymal fat of TRIP-Br2 KO mice placed on
either diet, revealed unchanged levels of adipose triglyceride lipase (ATGL)35 or its co-
regulators including CGI-58 and G0S2 (Fig 3e, 3f, Supplementary Fig. 17, 18), but a
significant increase in another key lipolytic enzyme, hormone sensitive lipase (HSL) at both
mRNA and protein levels36 (Fig. 3e, 3f, Supplementary Fig. 19), but not one of the HSL
regulators, Perilipin A. Interestingly, we observed an increased in Perilipin A gene
expression (Supplementary Fig. 17) but not in the protein level (Supplementary Fig. 18) in
the epididymal fat from the HFD fed KO mice. We also observed a significant increase in
the mRNA and protein expression of the β3-adrenergic receptor (Adrb3) in all adipose
depots from HFD fed KO mice (Fig. 3e, 3f).
Stimulation of Adrb3 signaling phosphorylates HSL and increases HSL-mediated lipolysis
leading to reduced fat mass37. Consistently, we observed an increase in HSL
phosphorylation in TRIP-Br2 KO mice (Fig. 3f). In the KO mice fed a LFD, a significant
increase in Adrb3 and HSL mRNA levels was detected in the epididymal WAT
(Supplementary Fig. 19). Consistent with the in vivo data, the gene and protein expression
of HSL and Adr3b were downregulated in differentiated 3T3-L1 adipocytes over-expressing
TRIP-Br2 and again ATGL was found to be unchanged (Fig. 3g).
Further, treatment of TRIP-Br2 KO adipocytes with a HSL specific inhibitor, 4-isopropyl-3-
methyl-2-[1-(3-(S)-methyl-piperidin-1-yl)-methanoyl]-2H-isoxazol-5-one (BAY)38,
completely prevented the increase in isoproterenol-stimulated lipolysis in TRIP-Br2 KO
adipocytes (Fig. 3h), confirming the role of HSL as the major lipolytic enzyme regulated by
TRIP-Br2 in the adipocyte.
To dissect the relative importance of β3-adrenergic receptor and HSL in the TRIP-Br2 KO
adipocyte, we stimulated isolated primary adipocytes with isoproterenol, forskolin or IBMX
to either activate the β3-adrenergic receptor or increase the cAMP level to indirectly
enhance HSL enzyme activity. Interestingly, isoproterenol-stimulated lipolysis showed a
tendency to be consistently higher compared to stimulation with forskolin or IBMX (Fig. 3i,
upper panel) suggesting that the primary site for action is an increase in β3-adrenergic
receptors in the TRIP-Br2 KO adipocyte. This observation was confirmed in the
differentiated TRIP-Br2 KD 3T3-L1 cell line (Fig. 3i, lower panel).
These results suggest that increased lipolysis in adipocytes and reduced adiposity in the KO
mice is mediated by specific regulation of β3-adrenergic receptors and HSL.
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Enhanced thermogenesis in TRIP-Br2 KO mice
Reduction in adipose tissue mass without alterations in food intake (Supplementary Fig 4a)
suggested a potential increase in energy expenditure in the KOs. Indeed, measurement of
oxygen consumption (VO2) rates over 48 h (light and dark phases) revealed ~20% higher
levels in the KOs (Fig. 4a) which could not be attributed to changes in activity
(Supplementary Fig. 20a). The rate of carbon dioxide elimination (VCO2) was unchanged
(Supplementary Fig. 20b). Consistent with the higher VO2, the KOs generated more heat
(Supplementary Fig. 20c), a ~0.7°C higher basal core body temperature (Fig. 4b, left panel),
and a higher body temperature for up to 3 h even in a cold environment (4°C) (Fig. 4b, right
panel), suggesting enhanced adaptive thermogenesis. The generally lower respiratory
quotient (RQ = VCO2/VO2) in the TRIP-Br2 KO mice indicated higher fat utilization
(Supplementary Fig. 20d). These data indicating increased thermogenesis in the TRIP-Br2
KO mice, prompted us to examine BAT. Notably, although we did not detect significant
alterations in the gross appearance or weight of interscapular BAT in the KO mice, we
observed a significant increase in the number of smaller adipocytes associated with smaller
lipid droplets (Fig. 1i, 2e). These results indicate that absence of TRIP-Br2 increases
thermogenesis, in part, due to an increase in brown adipocyte number.
Consistent with the increase in thermogenesis and VO2 in the KOs, we observed an up-
regulation of gene expression for uncoupling protein 1 (UCP1), PPARγ coactivator-1α
(PGC-1α), peroxisomal enoyl coenzyme A hydratase 1 (ECH1), cytochrome C (Cyc1) and
cytochrome c oxidase subunit VIIIb (Cox8b), which are genes involved in thermogenesis,
oxidative metabolism and mitochondrial biogenesis (Fig. 4c, left panel, Supplementary Fig
21). Further, examination of BAT in mice exposed to a cold environment revealed a
significant up-regulation in the expression of HSL and Adrb3 (Fig. 4c, right panel),
consistent with observations under ambient conditions (Fig. 3e). The cold exposed BAT
from the KO mice also showed a significant up-regulation of genes involved in
thermogenesis and in both mitochondrial and peroxisomal fatty acid oxidation (Fig. 4c, right
panel). Thus, ablation of TRIP-Br2 in brown adipocytes leads to up-regulation of Adrb3
expression and genes essential for adaptive thermogenesis and oxidative metabolism.
Considering Adrb3 signaling regulates thermogenesis and fatty acid oxidation pathways39,
the significant up-regulation of Adrb3 expression upon cold-exposure could potentially up-
regulate the genes involved in thermogenesis and fatty acid oxidation observed in BAT in
the KOs. These data were further supported by our observation that the BAT in TRIP-Br2
KOs exhibits a significantly higher oxygen consumption rate (OCR) (Fig. 4d) and increased
ratio of OCR to extracellular acidification rate (ECAR) (Fig. 4e) suggesting that the BAT
lacking TRIP-Br2 has enhanced oxidative metabolism compared to BAT in WT controls. To
further determine its role, we denervated the BAT and interestingly observed that this
manipulation only partially reverses the TRIP-Br2 obesity resistant phenotype (Fig. 4f)
suggesting contributions from other tissues.
In epididymal WAT of TRIP-Br2 KO mice, we detected an elevated expression of genes
(Fig. 4g, Supplementary Fig. 22), involved in promoting fatty acid oxidation. Consistently,
the basal and isoproterenol-stimulated fatty acid oxidation was enhanced in the isolated
primary TRIP-Br2 KO adipocytes (Fig. 4h). This observation was confirmed in vitro where
the basal and isoproterenol-stimulated fatty acid oxidation rates were reduced in the
differentiated 3T3-L1 adipocytes over-expressing TRIP-Br2, and conversely, enhanced in
adipocytes with a TRIP-Br2 knockdown (Figure 4i). The up-regulation of UCP1 and
oxidative metabolism genes are expected to result in the uncoupling of fatty acid oxidation
and the enhancement of in situ fatty acid utilization, which provide a plausible explanation
for the lack of increase in serum NEFA despite an elevated lipolytic activity in the WAT of
TRIP-Br2 KO mice. This hypothesis is further supported by unchanged fatty acid oxidation
in TRIP-Br2 KO skeletal muscle (Supplementary Fig. 23) a tissue known to be a major
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organ to utilize circulating free fatty acids. These findings suggest a model in which normal
TRIP-Br2 expression is permissive for the development of obesity and its related
complications through its effect on reducing energy expenditure and fat oxidation in
adipocytes by down-regulating the expression of key proteins involved in adipocyte
lipolysis, thermogenesis and oxidative metabolism (Fig. 5d).
TRIP-Br2 co-regulates HSL and Adrb3 transcription
We next used in silico sequence analysis to identify putative E2F consensus binding sites in
the promoter sequences of the mHSL and mAdrb3 (Supplementary Fig. 24) that were
conserved between the murine and human orthologs. Co-transfection of NIH-3T3 cells with
expression constructs of E2F1, E2F4, DP1 or TRIP-Br2 with luciferase reporter constructs
(pGL3) driven by the promoters of the mHSL or mAdrb3 genes revealed that over-
expression of either E2F1/DP1 or E2F4/DP1 transcriptional complex stimulates both HSL
and Adrb3 promoter-driven luciferase expression while the co-expression of TRIP-Br2
consistently repressed both promoter activities (Fig. 5a, Supplementary Fig. 25). These
results were confirmed by partial deletion and by site-directed mutagenesis of putative E2F
consensus binding sites. Our results show that the first two E2F sites in the HSL promoter
(−445 and −240), and both of the E2F sites in the Adrb3 promoters are responsive to both
E2F1/DP1 and E2F4/DP1 mediated transcriptional activation and TRIP-Br2 co-regulator
mediated transcriptional inhibition (Fig. 5a, Supplementary Fig. 25).
To confirm the binding of TRIP-Br2 on the mHSL and mAdrb3 promoters in vivo, we
performed chromatin immunoprecipitation (ChIP) in differentiated 3T3-L1 adipocytes
stably expressing TRIP-Br2-FLAG or empty vector control. Fragments of mHSL and
mAdrb3 promoters containing the E2F binding sites were enriched in the genomic DNA
immunoprecipitated from mTRIP-Br2-FLAG over-expressing adipocytes using an anti-
FLAG antibody and detected by qRT-PCR (Fig. 5b, left panel). Conversely, neither GAPDH
(negative control) nor the respective promoter regions lacking the E2F sites could be
detected in the immunoprecipitated genomic DNA samples (Supplementary Fig. 26). The
luciferase promoter analyses demonstrating co-repressor activity of TRIP-Br2 on the
transcriptional read-outs of the mHSL and mAdrb3 promoters were further confirmed by
showing decreased RNA polymerase II binding at the mHSL and mAdrb3 promoters in
mTRIP-Br2-FLAG over-expressing differentiated adipocytes (Fig. 5b, right panel).
To confirm the functionality of the E2F binding sites on the HSL promoter, we mutagenized
the first two endogenous E2F binding sites on the HSL promoter in 3T3-L1 cells using a
newly developed genome modification technique, TALEN (Transcription Activator-Like
Effector Nucleases)40. Mutagenesis of the HSL promoter E2F binding sites abolished the
enhanced isoproterenol-stimulated lipolysis observed in the differentiated TRIP-Br2 KD
3T3-L1 adipocytes (Fig. 5c), confirming the functionality and critical role of TRIP-Br2/E2F
regulation on HSL in the adipocyte.
Taken together, these data suggest that TRIP-Br2 is recruited as a co-repressor to novel
E2F1/DP1 or E2F4/DP1 complexes assembled on E2F consensus binding sites in the mHSL
and mAdrb3 promoters.
DISCUSSION
Over the past several decades, adipocytes have been the target of intense investigation due to
the dramatic emergence of obesity as a serious public health problem. Furthermore,
adipocytes have been shown to be critical integrators of various physiological pathways
regulating whole body glucose and energy homeostasis3. Identifying points of regulatory
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convergence that can serve as therapeutic targets to improve glucose and energy
homeostasis is therefore of great necessity.
Transcriptional co-regulators have been clearly identified as having dominant roles in
metabolism and energy homeostasis8,41. Despite the identification of numerous co-activators
and co-repressors (e.g. PGC1 and RIP140), most of the co-regulators have shown prominent
roles in fat accretion and adipocyte differentiation, primarily through the modulation of the
master regulator, PPARγ transcription factor. In this study, we identify a novel
transcriptional co-regulator, TRIP-Br2, for the regulation of adiposity and energy
metabolism and we also report a novel link between the cell cycle regulators (E2F family)
and energy homeostasis. To our knowledge, this is the first report of a cell cycle
transcriptional co-regulator capable of modulating fat storage by simultaneous regulation of
multiple processes including lipolysis, thermogenesis and oxidative metabolism, leading to
enhanced fatty acid turnover in adipocytes. TRIP-Br2 appears to be functionally different
from the other previously described transcriptional co-regulators, which regulate adipocyte
lipogenesis and differentiation. Our studies suggest that TRIP-Br2 mediates this metabolic
phenotype, in part, through transcription regulation of HSL and Adrb3 expression.
We observed that β-adrenergic agonist-stimulated lipolysis was markedly increased in in
vivo in the TRIP-Br2 KO mice as well as ex vivo in the isolated primary adipocytes from
TRIP-Br2 KO mice. Consistently, expression of HSL and Adrb3 were both significantly
enhanced in the adipose tissues from the KO mice suggesting that the enhanced stimulated
lipolysis is due to an increase in the expression of key proteins in the β-adrenergic regulated
lipolytic pathway. However, due to technical limitations in accurately monitoring the rate of
lipolysis by release of FA or glycerol, we are unable to rule out the effects of TRIP-Br2 KO
on FA re-esterification.
The enhanced lipolysis is consistent with the observation of smaller adipocytes and reduced
lipid accumulation in WAT and BAT of the TRIP-Br2 KO mice on a HFD. This finding is
consistent with other studies reporting a smaller fat pad and adipocyte size secondary to
increased lipolytic activity in the adipose specific desnutrin/ATGL overexpressors34 and the
adipose-specific phospholipase A2 (AdPLA) KO42 mice. Lipolysis in adipocytes is under
tight hormonal regulation and dependent on nutritional status. For example, during fasting,
increased levels of catecholamines bind to β-adrenergic receptors and promote the activation
of hormone sensitive lipase (HSL), whereas, in the fed state, lipolysis is inhibited by insulin.
Our data suggests that absence of TRIP-Br2 enhances the fasting stimulated β-adrenergic
regulated lipolytic activities.
However, it is evident that enhanced lipolysis alone may not be adequate to account for all
the observed phenotypes in the TRIP-Br2 KO mice, as demonstrated by a study in which
HSL over-expression failed to induce a lean phenotype in mice fed a HFD43. However,
unlike the simultaneous up-regulation of both HSL and Adrb3 due to ablation of TRIP-Br2,
Adrb3 was not simultaneously over-expressed in the HSL over-expression study. We
observed no significant increase in serum NEFA in the TRIP-Br2 KO mice. We hypothesize
that the lack of an increase in serum NEFAs despite enhanced lipolysis in TRIP-Br2 KO
mice reflects the use of alternative mechanisms that allows the utilization of excess fat and
FA in the mutant mice. Indeed, we observed enhanced fatty acid oxidation in the isolated
primary adipocytes from the TRIP-Br2 KO mice and in the differentiated 3T3-L1 adipocytes
with reduced expression of TRIP-Br2. In addition, the finding of increased oxygen
consumption and heat production in the KO mice also indicates an increase in energy
expenditure in vivo. The higher core body temperature and superior cold tolerance, both
indicate an increase in adaptive thermogenesis in the KOs. The energy expenditure
phenotype is consistent with a substantial up-regulation in the expression of genes that
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regulate thermogenesis, mitochondrial and peroxisomal FA oxidation in both WAT and
BAT. Further, ectopic expression of UCP1 in WAT has been reported to cause resistance to
diet-induced obesity with increased fatty acid oxidation in adipocytes44. Since peroxisomal
FA oxidation is associated with efficient uncoupling34,45, the elevated levels of peroxisomal
FA oxidation observed in TRIP-r2 KO mice is consistent with a switch from ATP
production to heat generation in WAT and BAT. In BAT, cold-induced PGC1α expression
has been reported to regulate thermogenesis by promoting mitochondrial respiration and by
uncoupling electron transfer from ATP synthesis through the induction of UCP146,47. In our
study, we observed that numerous genes involved in thermogenesis and FA oxidation were
up-regulated in cold-induced BAT in the KO mice. Together, our findings indicate that FA
liberated by enhanced lipolysis could potentially be used as fuel by the increased FA
oxidation and thermogenesis that together contribute to a leaner phenotype in the TRIP-Br2
KO mice.
Our data demonstrate that despite enhanced lipolysis in TRIP-Br2 KO mice, coordinate up-
regulation of fatty acid oxidation and thermogenesis in both WAT and BAT lead to
enhanced in situ fatty acid utilization as well as the absence of increased circulating NEFA
levels and ectopic fat accumulation in metabolic organs such as liver – a finding that is
clearly observed in WT mice fed with HFD. This hypothesis is further supported by a recent
observation that an increase in lipolysis and release of free fatty acids by the adipocytes
during weight loss or in fasting mice leads to an increase in inflammation in adipose
tissues48. In the TRIP-Br2 KOs, despite a striking increase in lipolysis, we observed
markedly less inflammation in the adipose tissues, consistent with our hypothesis that the
free fatty acid generated from the enhanced lipolysis is potentially utilized in situ in the
adipocyte rather than released into the circulation.
Cell cycle regulators have been increasingly implicated in the control of metabolism49. Our
data provide the first evidence that E2F/DP transcription complexes together with TRIP-Br2
regulate the β-adrenergic regulated lipolytic and mitochondrial beta oxidative pathways.
This is in contrast to the previous report that E2F1 and E2F4 modulation of PPARγ
transcription regulates adipocyte differentiation19,20.
The striking resistance to high fat diet-induced obesity and lean phenotype exhibited by
TRIP-Br2 KO mice and its selective elevation in visceral fat in obese humans makes it an
attractive therapeutic target for the treatment of obesity and obesity-related metabolic
diseases.
ONLINE METHODS
Animals
The creation of the original TRIP-Br2 knockout out bred mouse strain in the 129SvJ
background and the generation of a TRIP-Br2 inbred mouse strain on a C57BL/6
background by over 10 generations of backcrossing, has been previously reported21. Mice
were housed in pathogen-free facilities and maintained on a 12 hr light/dark cycle at the
Foster Biomedical Research Laboratory of Brande is University in Waltham, MA. All
protocols were approved by the Institutional Animal Care and Use Committee of the Joslin
Diabetes Center and Brande is University and were in accordance with NIH guidelines.
Subjects
Paired samples of visceral and subcutaneous adipose tissue were obtained from 178
Caucasian men (N=92) and women (N=86), who underwent abdominal surgery as described
in detail elsewhere50. The age ranged from 16 to 82 years and body mass index from 20.8 to
54.1 kg/m2. In these subjects, abdominal visceral and subcutaneous fat area was calculated
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using abdominal MRI scans or computed tomography scans at the level of L4–L5.
Percentage body fat was measured by dual-energy X-ray absorptiometry (DEXA).
Individual assigned to all three cohorts (lean: BMI<25; visceral obesity: visceral/
subcutaneous fat area > 0.4) fulfilled the following inclusion criteria: 1) Absence of any
acute or chronic inflammatory disease as determined by a leukocyte count > 7000 Gpt/l, C-
reactive protein (CRP) > 5.0 mg/dl or clinical signs of infection, 2) Undetectable antibodies
against glutamic acid decarboxylase (GAD), 3) No medical history of hypertension, i.e.
systolic blood pressure (SBP) was < 140mmHg and diastolic blood pressure (DBP) was <
85mmHg, 4) No clinical evidence of either cardiovascular or peripheral artery disease, 5) No
thyroid dysfunction, 6) No alcohol or drug abuse, 7) No pregnancy. All subjects had a stable
weight with fluctuations smaller than 2 % of the body weight for at least 3 months before
surgery. Normal glucose tolerance (NGT) was defined as fasting plasma glucose <6.0mmol/l
and a 120 min OGTT plasma glucose <7.8mmol/l. Impaired glucose tolerance (IGT) was
defined as fasting plasma glucose <6.0mmol/l and a 120 min OGTT plasma glucose
>7.8mmol/l and <11.1mmol/l. Type 2 diabetes was defined as fasting plasma glucose >
7.0mmol/l and/or a 120 min OGTT glucose >11.1mmol/l. The study was approved by the
ethics committee of the University of Leipzig. All subjects gave written informed consent
before taking part in the study.
Fasting plasma insulin was measured with an enzyme immunometric assay for the
IMMULITE automated analyzer (Diagnostic Products Corporation). Plasma leptin levels
were assessed by radioimmunoassay (Millipore). The OGTT was performed after an
overnight fast with 75 g standardized glucose solution (Glucodex Solution 75g; Merieux)
and insulin sensitivity was assessed with the euglycemic-hyperinsulinemic clamp method as
described51.
TRIP-Br2 mRNA expression in human visceral and subcutaneous adipose tissue
Human TRIP-Br2 mRNA expression was measured by quantitative real-time RT-PCR in a
fluorescent temperature cycler, and fluorescence was detected on an ABI PRISM7000
sequence detector (Applied Biosystems). Total RNA was isolated from paired subcutaneous
and omentaladipose tissue samples using TRIzol (Life Technologies), and 1 μg RNA was
reverse transcribed with standard reagents (Life Technologies). TRIP-Br2 mRNA
expression was determined by a premixed assay on demand: Hs00207372_m1 SERTA
domain containing 2 (Applied Biosystems). Samples were incubated in the ABI PRISM
7000 sequence detector for an initial denaturation at 95°C for 10 min, followed by 40 PCR
cycles, each cycle consisting of 95°C for 15 s, 60°C for 1 min, and 72°Cfor 1 min. TRIP-
Br2 mRNA expression was calculated relative to the mRNA expression of hypoxanthine
phosphoribosyltransferase 1 (HPRT1), determined by a premixed assay on demand for
human HPRT1 (Applied Biosystems). Amplification of specific transcripts was confirmed
by melting curve profiles(cooling the sample to 68°C and heating slowly to 95°Cwith
measurement of fluorescence) at the end of each PCR. The specificity of the PCR was
further verified by subjecting the amplification products to agarose gel electrophoresis.
Statistical analysis for human subject data
All analyses were conducted with the two genders considered together as well as separately.
TRIP-Br2 expression in subcutaneous and visceral fat was compared between lean and
obese subjects by means of t tests. The unadjusted correlation between TRIP-Br2 expression
and metabolic parameters was evaluated by means of Pearson’s correlation coefficients.
Adjusted correlation coefficients were derived from partial r2 obtained from ANCOVA
models that included each of the metabolic parameters and the visceral fat area as predictors
of TRIP-Br2 expression. The association between quartiles of TRIP-Br2 visceral fat
expression and risk of type 2 diabetes was evaluated by logistic regression with and without
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adjustment for visceral and subcutaneous fat areas and expressed by means of Odds Ratios
and their 95% CI.
Body weight study
For diet-induced obesity, all mice were fed a chow diet (21.6% fat, 23% protein and 55.4%
carbohydrate by kcal; #5020, LabDiet) until 6 weeks of age. Subsequently, mice were
assigned randomly to either a low-fat (10% fat, 20% protein, and 70% carbohydrate by kcal;
D12450B, Research Diets) or a high-fat diet (60% fat, 20% protein, and 20% carbohydrate
by kcal; D12492, Research Diets) until the end of the experimental protocol. Body weight
was measured weekly until 18 weeks of age.
Adipocyte size determination
Adipocyte cross-sectional area from caveolin (BD Biosciences) stained adipose tissue
images (150-200 adipocytes/mouse, 3 mice/genotype) was calculated using CellProfiler
image analysis software (Broad Institute, http://www.cellprofiler.org/)52,53
Fatty acid oxidation—Differentiated 3T3-L1 cells were treated with either vehicle or
isoproterenol for 1 hr. Cells were then washed and incubated with assay media containing
2% fatty acid-free BSA, 0.30 mM L-Carnitine, and 3H-palmitic acid (3 uCi/well) in low
glucose DMEM media for 1 hr. Fatty acid oxidation was determined by measuring 3H2O
production as previously described and normalized with total cellular protein45.
Isolated white and brown adipocytes were used to determine fatty acid oxidation by
measuring 14CO2 production from [U-14C] palmitic acid (0.2 uCi/ml) after incubation for 1
hr at 37°C with gentle shaking as previously described before normalized with total lipid
content54.
Genomic mutagenesis—Transcription Activator-Like Effector Nuclease (TALEN)
plasmid DNA was designed, synthesized and tested by Cellectis Bioresearch. Exchange/
integration matrix harboring the mutation was synthesized by GenScript. 3T3-L1
preadipocytes at 50-60% confluency were transfected with 1 μg of each TALEN plasmid
and exchange matrix using Lipofectamine2000 (Invitrogen). Twenty-four h after
transfection, cells were trypsinized and selected using puromycin. Colonies were then
picked and expanded before screening with PCR and confirmed with sequencing.
Adipose tissue oxygen consumption and extracellular acidification
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were
determined in mouse brown adipose tissue using a modified protocol55. Briefly, freshly
isolated BAT from WT and TRIP-Br2 KO mice (n = 5 per genotype) were rinsed with
unbuffered KHB medium containing 111 mM NaCl, 4.7 mM KCl, 2 mM MgSO4, 1.2 mM
Na2HPO4, 0.5 mM carnitine and 2.5 mM glucose. Adipose tissue was cut into small pieces
and rinsed with KHB medium, and 10 mg of tissue was placed in each well of a XF24-well
Islet Flux plate (Seahorse Bioscience). Then, 450 μl of KHB medium was added to each
well and samples were analyzed in an XF24 Extracellular Flux Analyzer (Seahorse
Bioscience) at 37°C56. The XF24 Analyzer mixed the media in each well three times for 2
min before measurements to allow oxygen partial pressure to equilibrate. Basal OCR and
ECAR were measured in all wells three times. Five tissue replicates from 5 mice per
genotype were analyzed in independent experiments and results were normalized to tissue
weight.
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Ex vivo lipolysis and lipogenesis
Isolated adipocytes were incubated with or without increasing doses of isoproterenol
(10−6-10−9 M), isoproterenol (5μM), forskolin (20μM) or IBMX (0.2μM) for 90 min.
Extracellular glycerol release was extracted and measured using Free Glycerol Reagent
(Sigma) as an indicator of lipolysis57. For the assessment of lipogenesis, isolated adipocytes
were incubated with [14C] deoxyglucose in the presence or absence of increasing
concentrations of insulin (0.1-100 nM) for 90 min. Incorporated radiolabeled glucose was
extracted and measured using liquid scintillation counting58.
Adipocyte differentiation
Mouse 3T3-L1 preadipocytes were grown in DMEM supplemented with 10% fetal bovine
serum (FBS). Two days after confluence, adipocyte differentiation was initiated with the
addition of 1.7 μM insulin, 0.5 mM isobutylmethylxanthine (IBMX) and 1 μM
dexamethasone in DMEM media supplemented with 10% FBS for 2 days, followed by 2
days in medium supplemented with insulin, and finally cultured for 4 days in normal growth
medium.
Tissue triglyceride analysis
Lipids from tissues were extracted with Folch solution consisting of a mixture of 2:1 (vol/
vol) chloroform/methanol as previously described59. Lipids were solubilized in 1% Triton
X-100 before evaporation under nitrogen gas. Triglyceride content was determined using
Triglyceride Determination Kit (Sigma).
Plasmid
Complete ORF of TRIP-Br2 was amplified from 3T3-L1 preadipocytes cDNA with PCR
using oligos carrying flag epitope-tag at the C-terminal from IDT and cloned into pBabe-
puro retroviral or pCDNA3.1 vector60. Mouse hormone sensitive lipase (HSL) or β3-
adrenergic receptor (Adrb3) promoter and respective deletion constructs were amplified
from 3T3-L1 preadipocyte genomic DNA with PCR using oligos from IDT and cloned into
pGL3 or pGL3-min-promoter luciferase vector respectively (Promega). All plasmids were
sequenced verified. Expression plasmids for E2F1, E2F4 and DP1 were gifts from L. Fajas
(Metabolism and Cancer Laboratory, INSERM, France)19.
Cell culture
3T3-L1 preadipocyte cell lines stably over-expressing TRIP-Br2-Flag were established by
infecting 3T3-L1 cells using retrovirus containing pBabe-puro-TRIP-Br2-flag construct,
followed by puromycin selection. The stable cell lines used in the experiments were mixed
clones from at least three independent viral productions, infections, and selections.
Antibodies
Rabbit polyclonal anti-TRIP-Br2 was raised against the peptide with the amino acid
sequence TRIP-Br2-25-39: DGPSKVSYTLQRQT and affinity purified with the antigen
(YenZym Antibody). Chicken polyclonal anti-HSL, anti-Adrb3, rabbit anti-perilipin A and
mouse anti-α-tubulin were obtained from Abcam. pHSL, pAkt, Akt, pERK, ERK, ATGL
antibodies were from Cell Signaling. PPARγ, CGI-58 and G0S2 antibodies were from Santa
Cruz.
Food intake, energy expenditure, physical activity and body composition
Food intake, physical activity, oxygen consumption (VO2), carbon dioxide (VCO2) and heat
production was measured using the Comprehensive Laboratory Animal Monitoring System
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(CLAMS; Columbus Instruments). The respiratory exchange ratio (VCO2/VO2) was
calculated from the gas exchange data and all data were normalized to lean body mass. Body
composition (fat and lean mass) was assessed by the Dual-Energy X-Ray Absorptiometry
(DEXA).
Body temperature and cold exposure
Body temperatures were assessed in 18-week-old male mice using a RET-3 rectal probe for
mice (Physitemp). Mice were exposed to an ambient temperature of 4°C in a cold room until
their core body temperature dropped to 25°C. Body temperatures were measured at 30 min
intervals using a digital thermometer.
Metabolic parameters
Plasma insulin was measured with an ELISA kit (Millipore). NEFA, TG and cholesterol
concentration in serum were measured with NEFA-C and Triglyceride E tests (Wako),
respectively. Serum adiponectin and leptin levels were measured with ELISA kits from
R&D Systems (Joslin DERC Assay Core).
Physiological studies and Histological analyses
Blood glucose was monitored with an automated glucose monitor (Glucometer Elite, Bayer).
Glucose tolerance tests and insulin tolerance tests were performed 16 hr after fasting as
described previously61. Mice were anesthetized, and tissues were rapidly dissected, weighed
and processed for immunohistochemistry as described previously61.
BAT denervation
In anesthetized mice, the posterior aspect around the neck and intra-scapular region were
first shaved and cleaned before a T-shaped incision (1/2 inch each direction) in the mid-
scapular region was made. Under a dissecting microscope, the intra-scapular fat pad was
carefully separated from the surrounding skin and a drop of 1% filtered sterilized toludine
blue was applied to the fat pad to allow visualization of the nerves. After careful separation
of the nerves from the surrounding tissues and vasculature around the fat pad, small nerves
were cut in 3 different locations and around 3mm segments of the larger nerves were
removed to prevent possible re-connection. Sham-operated animals were treated similarly
using the same procedure except cutting the nerves. After recovery, operated animals were
placed on HFD and monitored for their body weight and temperature until the end of the
experiment.
Reporter assay
3T3-L1 preadipocytes were cotransfected by Lipofectamine 2000 reagent (Invitrogen) with
HSL and Adrb3 reporter constructs, various combinations of pCDNA3.1-TRIP-Br2-Flag
and mammalian expression constructs expressing E2F1, E2F4, and DP1, along with a
promoterless Renilla luciferase construct. Lysates were collected 36 h after transfection, and
firefly and Renilla luciferase activities were measured with a Dual-Luciferase Reporter
System (Promega).
TAG hydrolase assay
To prepare the substrate for the TG hydrolase activity, triolein (Sigma) and [9,10-3H]
triolein (Perkin Elmer) as radioactive tracer was emulsified with phosphatidylcholine/
phosphatidylinositol (Sigma) using a sonicator. The final substrate concentration was 167
nmol of triolein/assay (8000 cpm of [9,10-3H] triolein/nmol). 100 μl with or without HSL
specific inhibitor were incubated with 100μl of the substrate (adipose tissue extract) in a
water bath at 37°C for 60 min. The reaction was terminated by adding 3.25 ml of methanol/
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chloroform/heptane (10:9:7) and 1 ml of 0.1 M potassium carbonate, 0.1 M boric acid, pH
10.5 before vortex twice for 30 s. After centrifugation at 3200 rpm for 15 min at room
temperature, the radioactivity in 1 ml of the upper phase was determined by liquid
scintillation counting.
Chromatin immunoprecipitation
Adipocytes derived from the Cont-3T3-L1 and TRIP-Br2-Flag-3T3-L1 cell lines were fixed
at day six of their differentiation by addition of 37% formaldehyde to a final concentration
of1% formaldehyde and incubated at room temperature for 10 min. Cross-linking was
stopped by addition of glycine to a final concentration of 0.125 M. Cells were then scraped
and samples were prepared using the EZ-Magna ChIP™ G Chromatin Immunoprecipitation
Kit (Millipore) according to the manufacturer’s protocol. The chromatin fractions were
incubated in each case with 10 μg of one of the following antibodies: anti-Flag M2 (F-1804;
Sigma), anti-RNA polymerase II and Normal IgG mouse (both provided by Millipore Kit),
Millipore) at 4 °C overnight with Magnetic Protein G Beads. After extensive washing and
final elution, the product was treated for 4h at 65°C to reverse cross-linking. Input DNA and
immunoprecipitated DNA were purified using kit column and analyzed by quantitative PCR
using Maxima™ Sybr Green qPCR Master Mix (Fermentas Life Sciences) with different set
of primers (both proximal and distal promoter regions) listed here. Mouse HSL proximal
promoter (F 5′-gcggaatggaaacagcgtagtgaa-3′, R 5′-tgttacctgccattgcttcggaga-3′), mouse
HSL distal promoter (F 5′-aacacagttcaagggctggagaga -3′, R 5′-caccatgtggttgctgggaattga
-3′), mouse GAPDH promoter 62 (F 5′-tactcgcggctttacggg-3′, R 5′-
tggaacagggaggagcag-3′), mouse β3 adrenergic receptor proximal (F 5′-
cttggatggtttgggttgttcggt -3′, R 5′-agggcttctgctgcaaagaagaga -3′) and mouse β3 adrenergic
receptor distal (F 5′-ttgtcccaaccaggacagaacaga -3′, R 5′-aagaaagccaggcacgttcacaag -3′).
Data were normalized by input values (for each set of promoter oligonucleotides) and
binding was expressed relative to the non-specific binding of IgG immunoprecipitated DNA
content.
Statistical analyses
All data are presented as mean ± SEM and analyzed by unpaired two-tailed Student’s t-test
or analysis of variance (ANOVA) as appropriate. A p-value less than 0.05 is considered
significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Regulation of TRIP-Br2 in obesity and effects of TRIP-Br2 ablation on obesity
(a) TRIP-Br2 mRNA and protein in brown adipose tissue (BAT), visceral (epididymal, Epi)
and subcutaneous (SubQ) white adipose tissue from low fat (LF) or high fat (HF) diet fed
C57BL/6J mice (n=7–9 per group). (b) Four- or 12- week old ob/+ or ob/ob mice (n=6 per
group). (c) Control or 3 month calorie restricted (CR) mice (n=5 per group). (d) Human
TRIP-Br2 mRNA in visceral fat from lean and men or women with SubQ or visceral obesity
(n=178). (e) Correlation of TRIP-Br2 mRNA expression in visceral fat with visceral fat area
in men and women. (f) Odds ratio (crude or adjusted for visceral and SQ fat area) of type 2
diabetes stratified by quartile expression of visceral TRIP-Br2 mRNA. (g) Body weights of
male WT, Het and KO on C57BL/6 background on either a LFD or HFD (n=7–9 per group).
(h) Body weights of male WT and KO in the original 129SvJ founder strain on HFD (n=3
per group). (i) Upper, representative photographs of male WT, Het and KO mice, fat pads
(BAT, SQ and epididymal) and livers of male WT, Het and KO mice fed with HFD. Lower,
body length, fat pad and liver weights in absolute amounts from male KO, Het and KO mice
fed with HFD. (j) Absolute and % body composition of male WT and KO mice fed HFD by
DEXA (n=6 per group). All data are presented as mean +/− SEM. *, p<0.05; **, p<0.01;
***, p<0.001.
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Figure 2. Effects of TRIP-Br2 ablation on glucose homeostasis and physiological parameters
(a) Glucose tolerance (left) and insulin tolerance (right) in male WT, Het, and KO mice fed
HFD (n=7–9 per group). (b) Plasma glucose, insulin, adiponectin, leptin and cholesterol in
male WT, Het and KO mice fed with HFD in the fed or overnight fasted states (n=7–9 per
group). adiponectin and leptin mRNA in Epi fat from male WT, Het and KO mice fed HFD
(n=7–9 per group). (c) Left, representative images of hematoxylin and eosin (H&E)-stained
sections of livers from male WT and KO mice fed HFD. Scale bar, 100 μm. Right,
triglyceride (TG) content of liver from male WT and KO mice fed HFD (n=5 per group). (d)
Left, representative images of H&E-stained sections of Epi fat from male WT and KO mice
fed HFD. Scale bar, 100 μm. Middle, quantification of F4/80+ crown-like structures in Epi
fat from male WT and KO mice fed HFD. Immunofluorescence images were used to
quantitate the % of crown-like structures. Three to five low power fields analyzed for 4 mice
per genotype (>1000 adipocytes per genotype). Right, F4/80 and MCP-1 mRNA in SubQ
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and Epi fat from male WT, Het and KO mice fed with HFD (n=7–9 per group). (e) Left,
representative images of H&E-stained sections of SQ, epididymal and BAT from male WT
and KO mice fed HFD. Scale bar, 100 μm. Right, brown adipocyte numbers in control and
KO BAT. (f) Left and middle, representative confocal images of caveolin-stained
epididymal adipose tissue and frequency distribution of adipocyte cell size in epididymal
adipose tissue from WT and KO mice fed with HFD. Right, triglyceride (TG) content of
epididymal and SQ from male WT and KO mice fed HFD (n=5 per group). Scale bar, 100
μm. All data are presented as mean +/− SEM. *, p<0.05; **, p<0.01; ***, p<0.001.
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Figure 3. TRIP-Br2 ablation enhances lipolysis by up-regulation of HSL and Adrb3 expression
(a) Ex vivo lipolysis in isolated SQ or BAT adipocytes from WT or KO mice (n= 5 per
group). (b) In vitro lipolysis in differentiated adipocytes expressing either empty vector
control, shTRIP-Br2 (left) or TRIP-Br2-flag (right) (n= 4 per group). (c) In vivo lipolysis in
WT or KO mice. Plasma glycerol (left) and FFA (right) were measured after administration
of β3-adrenergic receptor agonist. (d) In vivo lipolysis in epididymal or SQ fat from 18-
week old HFD fed WT or KO mice after 7 days of heavy water labeling. (e)β3-adrenergic
receptor (Adrb3), adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL)
mRNA in BAT, SQ and Epi fat from male WT, or KO mice fed HFD (n=7–9 per group). (f)
Western blotting for pHSL, HSL, ATGL and Adrb3 proteins in Epi or SQ fat from male
WT, Het and KO mice fed HFD (n=3 per group). (g) qPCR (left) or western blotting (right)
for lipolysis markers in differentiated 3T3-L1 adipocyte cells expressing either empty vector
control or TRIP-Br2-Flag (n=3 per group). (h) Lipolysis in adipocyte cell lysate from WT or
KO mice treated with or without forskolin and/or HSL inhibitor (BAY). (i) Upper, lipolysis
in isolated adipocytes from WT or KO mice or lower, differentiated adipocytes expressing
either control or shTRIP-Br2 treated with isoproterenol, forskolin or IBMX. All data are
presented as mean +/− SEM. *, p<0.05; **, p<0.01.
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Figure 4. TRIP-Br2 ablation promotes energy expenditure and fatty acid oxidation
(a) Oxygen consumption (VO2) analyzed by indirect calorimetry in WT or KO mice fed
with HFD (n=6 per group). (b) Left, rectal temperature measured for WT or KO mice fed
chow diet at room temperature (n=9 per group). Right, rectal temperature measured for WT
or KO mice on chow diet housed in a room at 4°C temperature (n=9 per group). (c) Left,
UCP1, PGC1α, ECH1, Cox8b and Cyc1 mRNA in BAT from male WT or KO mice after
fed with HFD (n=7–9 per group). Right, HSL, Adrb3, UCP1, PGC1α, NRF1, Tfam, Dio2,
PPARδ, Cpt1b, AOx and PhyH mRNA in BAT from male WT or KO mice after 3 h cold
exposure (4°C) (n=7–9 per group). (d) Oxygen consumption rate (OCR) (e) Ratio of OCR
and extracellular acidification rate (ECAR) of BAT from WT or KO mice analyzed by
Seahorse extracellular flux analyzer (n=5 per group). All data are mean +/− SEM. *, p<0.05;
**, p<0.01; ***, p<0.001. (f) Body weight of sham or BAT denervated WT or KO mice on
HFD after surgery. (n=5 per group). All data are presented as mean +/− SEM. *, p<0.05; **,
p<0.01 (vs sham WT); #, p<0.05 (vs denervated WT); +, p<0.05; ++, p<0.01 (vs sham KO).
(g) UCP1, PGC1α, ECH1, Cox8b and CAT mRNA in epididymal (Epi) WAT from male
WT or KO mice after fed with HFD (n=7–9 group). (h) Fatty acid oxidation in isolated
epididymal or SQ adipocytes from WT or KO mice on HFD. All data are mean +/− SEM. *,
p<0.05; **, p<0.01. (i) Fatty acid oxidation in differentiated 3T3-L1 adipocytes expressing
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either empty vector control, TRIP-Br2-Flag or TRIP-Br2 shRNA with or without
isoproterenol stimulation (n=3 per group). All data are presented as mean +/−SEM. *,
p<0.05; **, p<0.01 (vs control basal); #, p<0.05; ###, p<0.001 (vs control stimulated).
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Figure 5. TRIP-Br2-Flag represses HSL and Adrb3 gene expression by recruitment to novel E2F
consensus binding sites
(a) Luciferase reporter assay for HSL (left) and Adrb3 (right) promoters in NIH-3T3 cells
transiently transfected with plasmids (n=4 per group). Results were normalized to Renilla
luciferase activity and expressed as relative light units (RLU). All data are mean +/− SEM.
*, p<0.05; **, p<0.01; ***, p<0.001. (b) Chromatin immunoprecipitation (ChIP) assays for
TRIP-Br2 (left) and RNA polymerase II (right) on HSL, Adrb3 and GAPDH (control)
promoters in differentiated 3T3-L1 adipocytes expressing either empty vector control or
TRIP-Br2-Flag (n=3 per group). All data are mean +/− SEM. *, p<0.05. (c) Lipolysis in
control or TRIP-Br2 KD differentiated 3T3-L1 adipocytes with or without HSL promoter
E2F binding sites mutation stimulated with or without isoproterenol. (n=4 per group). All
data are mean +/− SEM. **, p<0.01. (d) Proposed model for the permissive role of TRIP-
Br2 in the complementary regulation of adipocyte lipolysis, thermogenesis and oxidative
metabolism.
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Table 1
Correlation between TRIP-Br2 Expression in visceral fat and antropometric and metabolic parameters.
Unadjusted Adjusted †
r P value r p value
Age 0.10 0.18 −0.02 0.79
Subcutaneous fat area 0.25 0.0008 0.10 0.18
Visceral fat area 0.55 <0.0001 - -
Body Fat 0.32 <0.0001 0.01 0.88
BMI 0.41 <0.0001 0.09 0.23
Waist-to-hip ratio 0.41 <0.0001 0.06 0.43
Total Cholesterol 0.39 <0.0001 0.06 0.46
HDL-C −0.15 0.033 −0.14 0.07
LDL-C 0.10 0.18 0.03 0.92
TG 0.41 <0.0001 0.07 0.33
FFA 0.28 <0.0001 0.04 0.64
Fasting plasma glucose 0.14 0.05 0.09 0.25
Fasting plasma insulin 0.41 <0.0001 0.16 0.03
HbA1C 0.35 <0.0001 0.18 0.015
2h OGTT plasma glucose 0.31 <0.0001 0.14 0.09
Clamp-GIR −0.48 <0.0001 −0.15 0.05
†Adjusted for gender and visceral fat area.
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